Author

Ana Laura Chiodetti

Immunocore (United Kingdom)ORCID 0000-0002-7243-2131Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Research Focus:host-pathogen & immune response· 2 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Assay:flow cytometry· 1 Organism:human· 1 Organism:mouse· 1 Assay:proteomics· 1

Frequent Co-Authors

Alexandra E. CuaycaliD· 1 shared Andrew M. LaddiD· 1 shared Andrew MuiriD· 1 shared Arianne C. RichardiD· 1 shared Audrey GérardiD· 1 shared Denise Minerva DrotariD· 1 shared Dylan SmurlickiD· 1 shared Edward A. PhelpsiD· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperBioengineering

Alexandra E. CuaycalORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Transient immune landscape remodelling shapes CD8 T-cell priming during infection

Ana Laura Chiodetti, Han Cai, Andrew Muir, Gracie J. Mead, Mariana Borsa, Arianne C. Richard, Audrey Gérard

The paper shows that transient immune architecture changes during infection protect low-affinity CD8 T-cell priming from Treg inhibition, ensuring broad T-cell responses.

bioRxiv · Mar 20, 2026 · PreprintImmunology

Inhibition of cell-mediated immunity in type 1 diabetes by beta cell-targeted PD-1 agonists in pancreas tissue slices

Matthew W. Becker, Matthew E. Brown, Katherine Wiseman, Ana Laura Chiodetti, Mollie K. Huber, Alexandra E. Cuaycal, Pumin Sintara, Sandra Mara Ferreira, Dylan Smurlick, Jessie M. Barra, Andrew M. Ladd, Denise Minerva Drotar, Mark A. Atkinson, Peter Weber, Hussein Al‐Mossawi, , Edward A. Phelps

This study shows that ImmTAAI, a beta cell-targeted PD-1 agonist, inhibits T cell activity in human type 1 diabetes by increasing T cell motility and reducing cytokine secretion.

bioRxiv · Oct 21, 2025 · PreprintBioengineering